Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax
- Friday, December 6, 2019, 7:09
- Finance
- Add a comment
LEXINGTON, Mass., Dec. 6, 2019 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its ongoing Phase 1 dose-finding study of…
About the Author
adminasapcorp has written 39417 stories on this site.